Business · Companies · 4 hrs ago
GC Biopharma wins 170 billion won for under-skin immune treatment
South Korean company GC Biopharma was selected for National Growth Fund support to develop an under-the-skin form of immunoglobulin.
The support totals 1.7 trillion won.
Immunoglobulin is made by separating and purifying antibodies from blood plasma.
It is used to supply antibodies to people with primary immunodeficiency and to treat some autoimmune and nervous system disorders.
The company says the funding will speed development of the treatment for the US.
The funding is intended to support this development, but no further steps or timeline were specified.
GC Biopharma was selected for support from South Korea’s National Growth Fund to develop subcutaneous immunoglobulin.
The support amounts to 170 billion won.
The company said it was selected on the 3rd, according to a report published on November 3, 2026.
Immunoglobulin is a plasma-derived medicine made by separating and purifying antibodies from blood.
It is used to supplement antibodies in people with primary immunodeficiency and to treat autoimmune and neurological diseases.
- Who
- GC Biopharma.
- What
- It was selected for 170 billion won in support to develop subcutaneous immunoglobulin.
- When
- November 3, 2026, according to the article’s publication date.
- Where
- Not stated.
- Why
- To support development of subcutaneous immunoglobulin.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Funding
- 170 billion won
- Company
- GC Biopharma
- Fund
- South Korea’s National Growth Fund
- Treatment
- Subcutaneous immunoglobulin
- Reported
- November 3, 2026
What people are saying
Speed up development of subcutaneous immunoglobulin in the US